Has pharma emerged from the ‘age of uncertainty’?

After years of disquiet and unpredictability in the pharma markets, a new age of megablockbusters, normalized M&A and more clarity around the Inflation Reduction Act has emerged, bringing the industry’s trajectory into better focus.

Following the COVID-19 pandemic, life sciences investment fell, and the sector struggled with strained cash for biotechs and an unwillingness on the part of Big Pharma to spend in the face of unknown risks.